Myriad Genetics, Inc. provided earnings guidance for the fiscal year 2022. For the year, the company expects revenue to be in the range of $670 million to $700 million and GAAP LPS to be in the range of $0.90 to $0.70.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.99 USD | -1.60% | -2.72% | +25.34% |
May. 13 | Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.34% | 2.17B | |
-6.26% | 12.09B | |
-3.26% | 8.21B | |
+5.19% | 5.74B | |
+31.20% | 5.64B | |
-9.05% | 4.16B | |
-56.99% | 2.88B | |
+11.87% | 2.69B | |
-7.86% | 2.33B | |
-4.87% | 1.86B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022